NanOlogy has transformed systemic chemotherapy into targeted delivery directly to the site of disease to enhance tumor kill and resulting immune response.
Starting with the world’s most prescribed systemic cancer agents, our proprietary submicron particle production technology platform uses sonic energy and supercritical fluid carbon dioxide to reduce paclitaxel and docetaxel API crystals by up to 400 times into stable, uncoated particles with exponentially increased surface area and unique geometry. Our patented submicron particles are suspended prior to use in simple vehicles and locally administered in a concentrated form directly to the site of disease where they have been shown to release drug for weeks at a time.
An extensive clinical trial program is underway for NanoPac® (sterile submicron particle paclitaxel suspension) including evaluation in prostate cancer, pancreatic cancer, pancreatic mucinous cysts, and peritoneal cancers (with orphan drug designation). NanoDoce® (sterile submicron particle docetaxel suspension) has begun a clinical trial in bladder cancer and will begin a clinical trial in renal cancer in mid-2019. NanoPac (submicron particle paclitaxel for nebulized inhalation) is completing IND-enabling studies to support clinical evaluation in 2019. A topical version of submicron particle paclitaxel is progressing a clinical trial in cutaneous metastases and has completed a phase 2 trial in actinic keratosis.
NanOlogy News
Upcoming NanOlogy Events
